What’s inside
View ResearchDiscover the potential of repurposing rituximab biosimilars for B cell-mediated autoimmune diseases. This study highlights rituximab's off-label success in treating 116 autoimmune conditions, originally approved for lymphoma. Explore its efficacy in targeting CD20+ B cells and the promising future applications in autoimmune therapy.
Repurposing Rituximab for Autoimmune Diseases
Comprehensive exploration of rituximab's repurposing for over 100 autoimmune diseases, highlighting its extensive off-label use and clinical success.
Rituximab Mechanism of Action
Rituximab's efficacy in treating autoimmune diseases stems from its three-fold mechanism of action: complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis, effectively eliminating CD20+ B cells.Detailed analysis of rituximab's three-fold mechanism targeting CD20+ B cells to treat various autoimmune conditions.
Comprehensive Rituximab Literature Review
In-depth review of rituximab's off-label use in 116 autoimmune diseases, supported by over 1,530 publications across 17 medical specialties.
Rituximab in Rheumatology
Examination of rituximab's application in over 40 rheumatological disorders, significantly alleviating inflammation and improving patient quality of life.
Rituximab for Neurological Disorders
Insight into rituximab's benefits for 40 neurological conditions, particularly multiple sclerosis, showing reduced disease signs and progression.
Dermatological and Endocrinological Uses of Rituximab
Overview of rituximab's effectiveness in treating pemphigus vulgaris and thyroid disorders, enhancing patient outcomes in dermatology and endocrinology.